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Abstract
MAMLD1 is thought to cause disordered sex development in 46,XY patients. But its role is
controversial because someMAMLD1 variants are also detected in normal individuals, sev-
eralMAMLD1mutations have wild-type activity in functional tests, and the maleMamld1-
knockout mouse has normal genitalia and reproduction. Our aim was to search for
MAMLD1 variations in 108 46,XY patients with disordered sex development, and to test
them functionally. We detectedMAMDL1 variations and compared SNP frequencies in con-
trols and patients. We tested MAMLD1 transcriptional activity on promoters involved in sex
development and assessed the effect of MAMLD1 on androgen production. MAMLD1
expression in normal steroid-producing tissues and mutant MAMLD1 protein expression
were also assessed. NineMAMLD1mutations (7 novel) were characterized. In vitro, most
MAMLD1 variants acted similarly to wild type. Only the L210X mutation showed loss of
function in all tests. We detected no effect of wild-type or MAMLD1 variants on CYP17A1
enzyme activity in our cell experiments, and Western blots revealed no significant differ-
ences for MAMLD1 protein expression. MAMLD1 was expressed in human adult testes and
adrenals. In conclusion, our data support the notion thatMAMLD1 sequence variations may
not suffice to explain the phenotype in carriers and that MAMLD1 may also have a role in
adult life.
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Introduction
TheMAMLD1 (mastermind-like domain-containing 1, previously also known as CXorf6) gene
(OMIM 300120) has been first identified in a patient with myotubular myopathy and male
hypogenitalism who was found to harbor a deletion on chromosome Xq28 [1, 2]. Meanwhile,
20MAMLD1 sequence variations have been described in patients who have a 46,XY disorder
of sex development (DSD), mostly presenting with hypospadias [3–9]. However, other forms
of DSD are also reported withMAMLD1 gene mutations. Some patients present with cryptor-
chidism [3, 4, 6] and/or microphallus [6, 7]. Recently, theMAMLD1 gene variation P677L was
found in a 46,XY patient with complete gonadal dysgenesis [10]. In addition, two 46,XY DSD
brothers with theMAMLD1mutation Q580R presented with female external genitalia. But
strikingly, their nephew with the same severe 46,XY DSD phenotype did not carry the muta-
tion [3]. By contrast, only one homozygousMAMLD1mutation (V505A) has been reported in
a 46,XX DSD subject with gonadal dysgenesis [11]. She presented with primary amenorrhea,
eunuchoidism, clitoromegaly and bilateral streak gonads [11].
Presently, there is some controversy about the causative role ofMAMLD1 gene variations
and the associated DSD phenotype in carriers for the following reasons. First, someMAMLD1
variants have also been detected in normal individuals (P359S, V505A, N662S) [3, 5, 7, 12] and
others are not present in all affected DSD individuals of the same family (P359S, Q580R) [3].
Second, the maleMamld1 knockout mouse has a normal genital phenotype and has normal
reproduction [13]. Third, functional studies in vitro show normal results for severalMAMLD1
mutations compared to wild type (WT) when studying their effect as suggested regulators of
genes involved in sex development [5, 14]. Finally,MAMLD1 variants are also found in other
species such as dogs, cats and horses with or without DSD [15–17].
Moreover, the V505A MAMLD1 variant has been found in the WT genome of the homo
Neanderthal and chimpanzee [18]. This variant is regarded as an ancestral, potentially com-
pensated mutation which is only disease-causing in humans [18]. Nevertheless, analyses of
large case-control studies revealed the double S-S haplotype including MAMLD1 P359S and
N662S as a risk factor for hypospadias [5, 7].
Little is known about the exact role of MAMLD1 in sexual development. A role in sex differ-
entiation through supporting testosterone production in critical periods of male development
has been suggested [14]. Studies in mice revealed increasingMamld1 expression from E12.5 to
E14.5 in fetal Leydig and Sertoli cells [13].MAMLD1 is controlled by SF-1 which is a key tran-
scription factor for numerous genes involved in sex development and steroidogenesis [14].
MAMLD1 transactivates also the non-canonical Notch targeted Hes3 promoter [14].Hes3 reg-
ulates cell differentiation and proliferation during embryonic development [19]. MAMLD1
seems related to the production of testosterone as its knock-down reduces testosterone produc-
tion and gene expression of CYP17A1 [20]. Studies inMamld1-KO mice showed significantly
reduced testicular expression of Leydig-specific genes such as Star, Cyp11a1, Cyp17a1,Hsd3b1
and Insl3, but normal expression of other genes related to steroidogenesis and sex-development
[13]. However,Mamld1-KO mice have normal external genitalia and are able to reproduce
similar to WT animals [13]. Taken together, there is justified doubt whetherMAMLD1 gene
variations are sufficient to explain the DSD phenotype in carriers warranting further studies.
In this study we searched forMAMLD1 sequence variations in a cohort of 108 46,XY DSD
individuals in whom mutations in other candidate genes (AR, SRD5A2, NR5A1) were previ-
ously ruled out. We found 9MAMLD1mutations (7 of them novel) in 108 46,XY DSD patients
(8.3%). Patients’ characteristics were compared to reported cases. In vitro functional studies
revealed negative results for mostMAMLD1 variants. Comparative alignments showed that
the original amino acids are mostly not conserved through evolution, yet V505 exists only in
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human. Overall, our data support the notion thatMAMLD1 sequence variations may not suf-
fice to explain the DSD phenotype in carriers.
Methods
Patients and genetic analyses
A cohort of 108 46,XY DSD individuals in whom mutations in other candidate genes (AR,
SRD5A2, NR5A1) were previously ruled out was analyzed forMAMLD1 sequence variation.
Written informed consent was obtained from all individuals participants/legal guardians
included in the study after full explanation of the purpose and nature of all the procedures
used. Each patient’s pediatric endocrinologist provided the clinical and biochemical data. The
genetic analyses were performed at the Vall d’Hebron Research Institute in Barcelona and the
in vitro and in silico functional studies were done at the Pediatric Endocrinology Research labo-
ratory in Bern. The molecular studies were approved by the ethic committees of the Vall
d’Hebron Research Institute, Barcelona, Spain and the Ethic Commission of the Kanton Bern,
Switzerland. Data entering the study were provided by the clinicians and the genetic lab in
coded forms and are stored and accessible to the scientific community as follows: a) requests
for clinical and biochemical data may be addressed to specific clinicians by contacting the cor-
responding author, b) genetic data are accessible through the Biobank system of Vall d’Hebron
(biobanc@vhir.org), c) relevant experimental data are provided as a Supporting file (S1 File).
The methods were carried out in accordance with the approved guidelines. Genomic DNA was
isolated from peripheral blood leukocytes.MAMLD1 coding regions, their flanking intronic
sequences and part of the 5’UTR were amplified by PCR using specific primers [S1 Table, [4]].
The PCR products were sequenced using the BigDye Terminator v3.1 Cycle Sequencing Kit on
an automated ABI PRISM 3100 Genetic Analyzer (Applied Biosystems, Foster City, CA, USA).
Obtained sequences were analyzed against GenBank entries NG_017093.2 (genomic DNA),
NM_005491.4 (mRNA) and NP_005482.2 (protein) (http://www.ncbi.nlm.nih.gov/). Genetic
analyses of the AR, SRD5A2 and NR5A1 genes were performed as described [21–23]. All
patients were checked for these 3 genes except patient 5, which was analyzed for NR5A1 only.
AMAMLD1 SNP genotyping (rs62641609: H347Q; rs41313406: P359S; rs61740566: V505A
and rs2073043: N662S) of 155 normal adult male controls was performed by TaqMan assays
for allelic discrimination using the Applied Biosystem Prism 7900 HT instrument and the alle-
lic discrimination end-point analysis mode of the Sequence Detection software package, Ver-
sion 2.3 (SDS 2.3). The following custom TaqMan SNP genotyping assays were used according
to the protocols supplied by Applied Biosystems: C__64647092_10; C__26000187_10;
C__25995288_20; C__15950293_10. Differences between controls and patients for SNP geno-
type and allele frequencies were analyzed with a contingency table analysis using the JMP17
program (SAS Institute, Inc., Cary, NC, USA).
Tissue expression studies
MAMLD1 expression was studied for normal human adrenal and testicular tissues using
cDNA samples purchased from amsbio (AMS Biotechnology (Europe) Limited, Abingdon,
UK). According to amsbio information, cDNAs originate from two adult subjects aged 50
years for adrenals and aged 23 years for testes. Fetal material was from two samples 20 weeks
gestation for adrenals and 30 weeks gestation for testes. Semiquantitative PCRs (35 cycles) for
MAMLD1 expression were carried out using the recommended concentrations of the pur-
chased cDNAs. Primers are listed in S1 Table. Agarose-gel electrophoresis was performed for
the PCR products, which were detected by ethidium bromide on a UV transilluminator
(Alphaimager, Proteinsimple, Santa Clara, CA, USA).
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In vitro functional and expression studies
Cell lines. Steroidogenic cell lines mouse Leydig MA-10 (ATCC CRL-305; http://www.
lgcstandards-atcc.org), human adrenal NCI-H295R (ATCC CRL-2128; http://www.
lgcstandards-atcc.org) and the non-steroidogenic, human embryonic kidney HEK293 cell line
(ATCC CRL-1573; http://www.lgcstandards-atcc.org) were used for this study. HEK293 cells
were cultured in DMEM, supplemented with 10% fetal calf serum, 1% penicillin/streptomycin
(Gibco, Paisley, UK) and 1% sodium pyruvate (Gibco). NCI-H295R cells were cultured in
DMEM/Ham’s F12 (1:1) (Gibco), supplemented with 5% Nu serum (Becton Dickinson AG,
Allschwil, Switzerland), 1% penicillin/streptomycin and 0.1% ITS Premix (Becton Dickinson).
MA-10 cells were cultured in Waymouth MB 751/1 (Sigma-Aldrich Corp., St. Louis, MO,
USA) supplemented with 15% Horse Serum (Gibco) and 1% penicillin/streptomycin (Gibco).
Expression vectors. The promoter luciferase reporter vector Hes3_luc (-2715~+261) was
kindly gifted by Dr. Maki Fukami (National Research Institute for Child Health and Develop-
ment, Tokyo, Japan) [14, 24]. The human -3.7CYP17A1_Δluc vector was available from previ-
ous work [25, 26]. For the MAMLD1 expression vectors, we used the WT cMyc-
MAMDL1_pCMV and the minor transcript variant lacking exon 5 ΔE5 (previous ΔE4), both
kindly gifted by Dr. Maki Fukami. In addition, we modified the WT cMyc-MAMLD1_pCMV
vector according to the revised coding sequence NM_005491.4 (GenBank MAMLD1, isoform
2, new transcription start site in r.64, exon 2). This newWT construct was custom made by
GenScript (Piscataway, NJ, USA). Mutant MAMLD1 expression vectors (c.605C>T,
c.626delT, c.631G>A, c.1041C>A, c.1075C>T, c.1508C>A, c.1514T>C, c.1985A>G,
c.2170C>G and c.2190G>A) were generated by PCR-based site-directed mutagenesis using
specific primers (S1 Table) and the QuickChange protocol by Stratagene (Agilent Technologies
Inc., Santa Clara, CA, USA) using the newWT expression vector as template. The MAMLD1
mutant c.1503_1504dupCAGCAG was also custom made by GenScript. All new constructs
were verified by direct sequencing.
MAMLD1 promoter transactivation experiments. Cells were cultured on 24-well plates
and transiently transfected (Lipofectamine 2000TM, Invitrogen) with WT or mutant
MAMLD1 together with the promoter luciferase reporter constructs Hes3_luc or
-3.7CYP17A1_Δluc for 6 hours. The transfection mixture contained 1.25 μg of plasmid DNA
and 50 ng Renilla of luciferase reporter (pRL-TK) control per well. Forty-eight hours after
transfection, cells were washed with PBS, lysed and assayed for luciferase activity with the
Dual-Luciferase Reporter (DLR™) Assay System (Promega AG, Wallisellen, Switzerland) on a
Veritasmicroplate Luminometer reader (Turner BioSystems Luminometer and Software by
Promega). Firefly luciferase readings were standardized against Renilla control readings and
results expressed as relative luciferase units (RLU). Experiments were performed in duplicates
and repeated 3 times. Data are given as mean±SEM. Statistical significance was examined using
Student’s t-test (Microsoft Excel). P-value for significance was set at0.05.
CYP17A1 enzyme conversion experiments. To measure a possible effect of MAMLD1 on
CYP17A1 activity, we assessed the conversion of progesterone to 17-hydroxyprogesterone and
androstenedione in steroidogenic NCI-H295R and MA-10, and non-steroidogenic HEK293
cells. For this, all cells were transfected with WT or mutant MAMLD1 and non-steroidogenic
HEK293 cells in addition with human CYP17A1 in pcDNA3. Experiments were performed on
12-well plates; transient transfection was for 6 hours (1.25 μg plasmid DNA/well) and experi-
ments were closed after 48 hours. Steroid conversion was labeled by adding 20,000 cpm14C-
progesterone per well for 60 min before extracting all steroids from the cell medium. Steroids
were then separated by thin layer chromatography (TLC; Macherey-Nagel, Düren, Germany)
using the chloroform:ethylacetate (3:1) solvent system and steroid standards. TLC plates were
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exposed on imaging screens to visualize the radioactive steroids. The screens were read on a
Fuji PhosphoImager Fla-7000 (Fujifilm, Dielsdorf, Germany). Steroids were identified accord-
ing to known stardards and densitometrically quantified as % of total radioactivity per sample
using Multi Gauge software (Fujifilm). Experiments were performed 2 times in 3 different cell
line backgrounds.
MAMLD1 protein expression studies. Leydig MA-10 cells were transiently transfected
with either WT (WT, original WT of ΔE5) or mutant MAMLD1 expression vectors, which all
carried a Myc-tag. Cells were lysed and a Western blot was performed using an antibody
against c-Myc (C6594, Sigma, Saint Louis, USA). Experiments were repeated twice. Expression
of β-actin was the control.
In silico analysis
The following databases and computational tools were used. CLC Sequence Viewer software
(2014 CLC bio, QIAGEN) was used to search for homologies of MAMLD1 through species.
Polymorphism Phenotyping v2 (PolyPhen-2, http://genetics.bwh.harvard.edu/pph2/index.
shtml) [27] was used to predict the possible impact of amino acid substitutions on the structure
and function of MAMLD1. We searched for functional partners of MAMLD1 with the Search
Tool for the Retrieval of Interacting Genes/Proteins (STRING, http://string-db.org/), devel-
oped at the Center for Protein Research (CPR), EMBL, Swiss Institute of Bioinformatics (SIB),
University of Copenhagen (KU), Technical University of Dresden (TUD) and University of
Zurich (UZH). The Biological General Repository for Interaction Datasets (BioGRID,
thebiogrid.org), developed at Princeton University, University of Montreal, University of Edin-
burgh and Mount Sinai Hospital, is a public database that was searched for protein
interactions.
Results
Patients’ genotypes and phenotypes
We searched for mutations in the MAMLD1 gene (Fig 1A) in a cohort of 108 46,XY DSD
patients from Spain and Switzerland.MAMLD1 is located on Xq28. The originalMAMLD1
gene sequence has been recently revised [6] for a new upstream transcriptional start site (TSS):
+64 (exon 2) (old TSS +284) which has caused a renumbering of exons and sequence (http://
www.ncbi.nlm.nih.gov/gene/10046) and a renaming of the previously identified mutations (Fig
1). MAMLD1 presents with 3 different isoforms (Fig 1A). Isoform 2 (NM_005491.4,
NP_005482, ENST00000262858, 774 amino acids), which is coded by exons 2 to 7, is consid-
ered the canonical sequence and has been studied previously [3, 6, 10, 11, 14]. Isoform 3
(NM_001177466, NP_001170937, ENST00000426613, 749 amino acids) is identical to isoform
2, but lacks exon 3. Isoform 1 (NM_001177465, NP_001170936, ENST00000432680, 998
amino acids) has a non-coding upstream codon, lacks exon 3, and has a different C-terminus
compared to isoforms 2 and 3 due to a translational frameshift after exon 4.
In our cohort of 46,XY DSD a total of 9 sequence variations were detected (Fig 1B). Three
MAMLD1 sequence variations were considered SNPs, but had been previously described in
both controls and 46,XY DSD individuals (rs41313406: c.1075C>T, P359S; rs61740566:
c.1514T>C, V505A and rs2073043: c.1985A>G, N662S) [3–7, 14]; one was previously detected
in 46,XY patients only (rs62641609: c.1041C>A, H347Q) [6], and 7 were novel (c.605C>T, p.
T202M; c.626delT; p.L210X; c.631G>A, p.D211N; c.1503_1504dupCAGCAG, p.Q501Q502;
c.1508C>A, p.A503E; c.2170C>G, p.L724V and c.2190G>A, p.S730S). Nine sequence varia-
tions found in 9 patients were considered potentially pathogenic. These patients manifested
with a broad range of 46,XY DSD phenotype (Table 1). Six patients presented rather severe
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hypospadias, 2 also had cryptorchidism, and 1 presented with normal external female genitalia
with gonads palpable in the genital folds. Four 46,XY subjects were reared as females, 5 as
males. Testis histology was studied in 3 patients between age 2 weeks and 2 years and was nor-
mal. Hormonal studies for gonadal function demonstrated normal baseline and/or hCG stimu-
lated testosterone production and normal AMH levels (Table 1). Subject 5 claimed to have
fathered a child. Adrenal function tests were normal in all tested patients. Additional diagnoses
were present in 3 patients, 1 related to a 22q11 deletion syndrome (subject 8, Table 1).
MAMLD1 polymorphism testing
We chose 4MAMLD1 variants (H347Q, P359S, V505A and N662S), previously detected in
controls and 46,XY DSD patients [3, 5–7] and/or referenced in dbSNP (http://www.ncbi.nlm.
Fig 1. MAMLD1 transcripts, reportedmutations and tissue expression. A. Schemes of the 3 MAMLD1 human transcripts are shown (http://www.ncbi.
nlm.nih.gov/; http://www.ensembl.org). B. Scheme showing all reportedMAMLD1 gene mutations. Mutations described in this study are shown in red and the
novel ones are marked with an asterisk. C. Assessment of MAMLD1 expression in human fetal and adult adrenal and testis. Semiquantitative RT-PCRs were
performed using specific primers (S1 Table). GAPDH was used as the internal control. A representative gel picture is shown (n = 3). For MAMLD1 the band at
581 bp corresponds to isoform 2 and the band at 506 bp to isoforms 1 and 3. Dashed red lines in A indicate the location of the PCR fragments amplified for
the expression studies.
doi:10.1371/journal.pone.0142831.g001
Role ofMAMLD1 in 46,XY DSD
PLOSONE | DOI:10.1371/journal.pone.0142831 November 16, 2015 6 / 20
nih.gov/snp/) to compare their genotype and allele frequency in a cohort of 155 normal adult
male controls (Table 2) and our cohort of 108 46,XY patients (Table 2) (with phenotypes vary-
ing from penoscrotal hypospadias to female external genitalia and including the 9 in whom
MAMLD1 sequence variations were detected, Table 1). The MAMLD1 variants H347Q and
V505A were not found in our 155 normal adult male controls suggesting a causative role for
these genetic variations; the H347Q variant was not present in two exome pools of the Euro-
pean population (http://evs.gs.washington.edu/EVS/ and.http://exac.broadinstitute.org/about),
but the V505A was detected in 0.05% and 0.1% of these European subjects, and in 17.8% of
African people (http://exac.broadinstitute.org/about). The variants P359S and N662S were also
Table 1. Clinical, biochemical and genetic characteristics of the patients harboringmutations and polymorphisms in theMAMLD1 gene.
Patient Origin, YOB Karyotype,
Assigned
sex
MAMLD1 gene mutation Genital anatomy Testes
histology
(age)
Gonadal function
(age)
Adrenal
function
(age)
Remarks
1 Spain, 2009 46,XY, Male T202M, c.605C>T Penoscrotal
hypospadias.
Small penis.
Unilateral
cryptorchidia.
Normal T
(minipuberty).
Normal
gonadotropins. No
hCG test.
ND SGA. Short
stature. Low
implantation
thumbs.
2 Spain, 1999 46,XY,
Female
L210X, c.626delT and
D211N, c.631G>A
Penoscrotal
hypospadias.
Small penis.
Testes 0.5 ml.
Normal for
age (15 d).
Normal T
(baseline) and
hCG test (10
days).
Normal
baseline
(15 d).
Abnormal GGN
repeat in AR.
Mother non-
carrier;
norﬂoxacine
treatment during
pregnancy.
3 Spain, 2005 46,XY,
Female
H347Q, c.1041C>A,
rs62641609
Female genitalia.
Gonads in labia.
Normal hCG test
(2 y).
Normal
baseline (2
y).
4 Spain, 2008 46,XY, Male H347Q, c.1041C>A,
rs62641609
Penoscrotal
hypospadias.
Testes 2 ml.
Normal hCG test.
Normal AMH (2.5
y).
Normal
baseline
(2.5 y).
5 Switzerland,
1942
46,XY, Male Q501Q502,
c.1503_1504dupCAGCAG
Hypospadias.
Short penis.
Delayed puberty.
Testes 8 ml.
Baseline T and
gonadotropins
normal (70 y).
Fathered a boy.
Normal
baseline
(70 y).
6 Spain, 2001 46,XY, Male A503E, c.1508C>A Penoscrotal
hypospadias.
Small penis.
Testes 2 ml.
Normal baseline T
(3 m). Normal
hCG test (9 m).
Normal
baseline (3
d).
7 Spain
(Venezuelan
origin), 2000
46,XY,
Female
V505A, c.1514T>C,
rs61740566
Penoscrotal
hypospadias.
Small penis.
Unilateral
cryptorchidia.
Normal for
age (2 y).
Normal hCG test. Normal
Synacthen
test.
8 Spain (North
African origin),
2010
46,XY, Male L724V, c.2170C>G Penoscrotal
hypospadias.
Small penis.
Testes 1 ml.
Normal
prepubertal
baseline T (15 m).
Normal AMH.
Normal
baseline
(15 m).
Esophageal
atresia. Right
aortic arch.
9 Spain, 1990 46,XY,
Female
S730S, c.2190G>A Penoscrotal
hypospadias.
Small penis.
Normal for
age (nests of
Normal Leydig
cells; normal
fertility index
(1 y).
Normal baseline
(12 m). No hCG
test.
Müllerian ducts.
ND: not done. d: day(s), m: month(s), y: year(s).
doi:10.1371/journal.pone.0142831.t001
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quite frequently found in our controls (Table 2), and frequencies were similar in the databases.
Linkage analysis of variants P359S and N662S was positive for 84% and 92% of controls and
46,XY DSD carrying the N662S variant (Table 2), thus indicating high co-segregation of both
variants.
MAMLD1 tissue expression
We studied MAMLD1 expression for human fetal and adult adrenal and testis tissues. We
found that MAMLD1 is expressed in the adult adrenal and testis, and the fetal testis. No
expression was found in the fetal adrenal (Fig 1C). We detected all 3 isoforms in similar
quantities.
In vitro and functional studies
In 2012 the reference sequence ofMAMLD1 has been revised (GenBank NM_005491.4, [6]).
Therefore, we modified the human MAMLD1 expression plasmid which has been originally
used for functional studies in all published studies accordingly. We then first performed pro-
moter transactivation studies (Fig 2) with the Hes3 promoter reporter in non-steroidogenic
HEK293 cells to compare the activity of the revised MAMLD1WT vector with the original
WT (Fig 2A). We found similar transactivation activity on theHes3 promoter construct for
both WT isoforms (revised and original) as well as for the revised shorter isoform without
exon 5.
We then created mutant MAMLD1 expression vectors by site-directed mutagenesis accord-
ing to identified sequence variations in our 46,XY DSD patients. For unclear test results in the
literature [3, 5, 7, 14], we added MAMLD1 P359S and N662S to our test series. The ability of
these 11 MAMLD1 variants to transactivate theHes3 promoter in HEK293 cells was then
assessed (Fig 2B). Surprisingly, only the L210X mutant lost transcriptional activity compared
to WT.
Given these results, we performed similar studies with the human CYP17A1 promoter
(Fig 3), as studies in mice revealed an effect of MAMLD1 on CYP17A1 expression, activity and
testosterone production [13, 20]. Again, most MAMLD1 variants showed WT effect on the
CYP17A1 promoter reporter (Fig 3A). Similar to theHes3 promoter, mutant L210X showed a
loss of activity on the CYP17A1 promoter, while variants L724V and S730S showed a decrease
in promoter activation compared to WT (p = 0.052 for S730S).
Next, we also tested the effect of WT and MAMLD1 variants on CYP17A1 enzymatic activ-
ity. For that we transfected MAMLD1 expression vectors into human adrenal NCI-H295R and
into mouse Leydig MA-10 cells. We also co-transfected MAMLD1 expression vectors together
Table 2. Study of polymorphisms in theMAMLD1 gene.
Controls (n = 155) 46,XY DSD (n = 108)
Sequence change, NM_005491.3 (NT_167198.1/ U46023) Allele Frequency (n) Frequency (n)
H347Q (H274Q) rs62641609 C 1.00 (155) 0.98 (106)
A 0.00 (0) 0.02 (2)
P359S (P286S) rs41313406 C 0.85 (134) 0.90 (97)
T 0.15 (21) 0.10 (11)
V505A (V423A) rs61740566 T 1.00 (155) 0.99 (107)
C 0.00 (0) 0.01 (1)
N662S (N589S) rs2073043 A 0.84 (130) 0.89 (96)
G 0.16 (25) 0.11 (12)
doi:10.1371/journal.pone.0142831.t002
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with a CYP17A1 expression vector into non-steroidogenic HEK293 cells. After transfection,
activity of CYP17A1 was assessed by measuring the conversion of radiolabeled progesterone to
17-hydroxyprogesterone (Fig 3B, S2 Fig). We found no difference for CYP17A1 activity for
WTMAMLD1 and variants in all 3 cell systems (data for NCI-H295R cells in Fig 3B; data for
MA-10 and HEK293 in S2 Fig). Remarkably, there was also no difference between the control
vector and the WTMAMLD1 indicating that MAMLD1 does not regulate human CYP17A1
activity or that the effect is indirect through essential co-factors that were not present in the 3
cell systems used for our experiments.
SomeMAMLD1 nonsense mutants have been suggested to affect protein expression by non-
sense mediated RNA decay [E197X (old E124X), Q270X (old Q197X) and R726X (old R653X)
[3]]. Therefore, we analyzed protein expression of WT and mutant MAMLD1 in MA-10 cells.
Cells were transfected with the MAMLD1 expression vectors containing a Myc-tag, then West-
ern blots were performed using an antibody against c-Myc (Fig 4). We found no significant dif-
ference for MAMLD1 protein expression for almost all of the tested variants compared to WT.
The L210X mutant presented a lower band on the Western blot according to its shorter length
and its amount may therefore not be compared to the full-length missense variants.
In silico analyses
PolyPhen-2 (http://genetics.bwh.harvard.edu/pph2/index.shtml) [27] was used to predict the
possible impact of amino acid substitutions due to missense mutations T202M, D211N, P359S,
H347Q, A503E, V505A, N662S and L724V on the structure and function of MAMLD1
(NP_005482.2). Using standard parameters [27], only T202M, H347Q and L724V were con-
sidered probably damaging.
Variants T202M, D211N, H347Q, P359S and A503E are predicted to impact on protein
function because the amino acid change comprises a change in the physico-chemical property.
Proline is a bending amino acid, thus it may cause a change in the conformation of the protein
Fig 2. Transactivation activity of MAMLD1 on theHes3 promoter. HEK293 cells were transiently transfected with wild-type (WT) and mutant MAMLD1
expression vectors and with a Hes3 promoter luciferase reporter construct. Luciferase activity was measured with the Promega Dual Luciferase assay
system. A. Comparison of the newly constructed MAMLD1WT expression vector (WT (a), NM_005491.4) with the older WT (WT (b)), and ΔE5 (ΔE5 (b))
constructs [14]. Similar transactivation activity on theHes3 promoter was found for all constructs. B. Hes3 transactivation byWT and the 11 MAMLD1
mutants was assessed. Only the L210X MAMLD1mutant showed an impaired activity on the Hes3 promoter. Results are expressed in relative light units
(RLU) and represent the mean and SEM of 3 independent experiments performed in duplicate. ΔE5: original WT (b) without exon 5 [14]; * p0.05.
doi:10.1371/journal.pone.0142831.g002
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and it is therefore considered important. According to this, P359 could have some effect on the
protein function, although it is not a conserved position in mammals (S1 Fig).
Furthermore, we aligned the human MAMLD1 isoform 2 (774 amino acids) with homolo-
gous sequences (ranging 720–820 amino acids) from 40 mammalian species with the CLC
Sequence Viewer software (S1 Fig). To study all detected species available in the NCBI database
(e.g. beyond mammals) was not possible because of high variability in length. L210 and L724
(1 change each) are conserved along mammalian evolution, followed by S730 (deleted amino
acid (-) in 2 species). They might therefore be of importance for protein function. The remain-
ing variants’ positions T202, D211, P359, Q501Q502, A503, V505 and N662 are not conserved
and therefore not considered important for protein function. Variants in positions 202, 347,
Fig 3. Effect of MAMLD1 on CYP17A1 promoter and enzyme activities.HEK293 cells or NCI-H295R
cells were transiently transfected with MAMLD1WT and mutant expression vectors. For promoter activation
studies, the (-3.7kb)CYP17A1 promoter luciferase reporter construct was co-transfected. A. CYP17A1
promoter activation by MAMLD1 was assessed by the Promega Dual luciferase assay in HEK293 cells. Only
for mutant MAMLD1 L210X and L724V an impairedCYP17A1 activation was found. Results are expressed in
RLU and represent the mean and SEM of 3 independent experiments performed in duplicate. B. The effect of
WT and mutant MAMLD1 on CYP17A1 enzyme activity was assessed in transfected NCI-H295R, MA-10 and
HEK293 cells by measuring the conversion of progesterone to 17-hydroxyprogesterone. Steroid production
was labeled with [14C]progesterone for 60 min. Steroids were extracted and resolved by thin-layer
chromatography, then quantified as % conversion. A representative steroid profile obtained from NCI-H295R
cells is shown (n = 2). No effect of MAMLD1 on CYP17A1-hydroxylase activity was detected. P:
progesterone; 17OHP: 17-hydroxyprogesterone; RLU: relative light units; Ve: empty vector; WT: wild type;
NT: non-transfected; * p0.05.
doi:10.1371/journal.pone.0142831.g003
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505 and 662 are WT in other mammals indicating that these amino acid changes may not be of
importance. T202 and S202 are similarly found: T202 is present in one third of the species (pri-
mates and bovidae), while the other mammals present S202. For position 347, H is mainly
present, but 2 other changes, including our variant Q347 (in 10 species), are seen. V505 is only
present in human, whereas most other mammals harbor A505 (27 species), suggesting that
human V505A may just be a reversion to the ancestral state. In position N662 4 variants are
present including the variant S662. Finally, the duplication Q501Q502 lies in a Q sequence,
which has variable length in different species. This indicates that the length change may not
harm the protein function.
Discussion
We detected 7 novel and 2 previously publishedMAMLD1 sequence variations in 9 46,XY
DSD patients presenting with a broad phenotype (Table 1). Similar to other studies, we found
that forMAMLD1 sequence variations genotype-phenotype correlation and functional studies
reveal ambiguous results. In our series only the truncatedMAMLD1 L210X mutation, found in
a severely affected 46,XY DSD patient, showed loss of function in transactivation assays using
theHes3 and the CYP17A1 promoters as interacting partner. L201X can therefore be consid-
ered a deleterious mutation. Remarkably, this patient also presented with hypogonadotropic
hypogonadism at pubertal age suggesting that MAMLD1 may also be involved in the HPG
axis, what has not been described so far, or that the patient may harbor additional genetic
defects. By contrast, L724V, carried by a 46,XY DSD patient with a typical MAMLD1 pheno-
type (46,XY male with penoscrotal hypospadias and small penis), and the synonymous S730
mutation, found in 46,XY female patient (also with penoscrotal hypospadias and small penis),
had only impaired CYP17A1 but normal Hes3 transactivation activity. Both positions are con-
served in mammals. Although variant H347Q showed no functional impairment in our in
vitro tests, its presence in 2 of our patients with a severe 46,XY DSD phenotype (female and
ambiguous genitalia) and in a published 46,XY DSD patient with hypospadias and microphal-
lus [6], as well as its absence in 155 control males suggests a disease causing role. Variant
V505A, which we found in one patient, has been previously described in 2 46,XY DSD subjects
[4, 7] and in a 46,XX dysgenetic woman [11]. Interestingly, this human variant is the WT
Fig 4. Protein expression of MAMLD1.Mouse testis Leydig MA-10 cells were transiently transfected with Myc-tagged expression vectors for WT or mutant
MAMLD1. Cells were lysed andWestern blot (WB) was performed using anti-Myc antibody. B-actin was the control. A representative WB is shown. Two
independent experiments were performed showing no significant variation in protein expression for wild-type (WT) or mutant MAMLD1. L210X gave a shorter
protein. Ve: empty vector; WT: wild-type; WT(a): original WT construct; ΔE5(a): original construct lacking exon 5 [14].
doi:10.1371/journal.pone.0142831.g004
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found in the genome of the Neanderthal, the chimpanzee and many other species and has been
discussed to be an ancestral, potentially compensated mutation [18].
According to published literature of microdeletions and rearrangements in the Xq28 region
containing the MAMLD1-MTM1-MTMR1 genes [see Table 3 and [1, 2, 28–30]], which causes
myopathy for the involvement of the MTM1 gene, it appears for the DSD phenotype that the
C-terminal region of the MAMLD1 gene is critical for abnormal sex development [29]. By con-
trast, MAMLD1 variants which have been associated with DSD are found throughout the gene
(Fig 1B).
To test novel MAMLD1 sequence variations for their disease causing role, we used Hes3
promoter activation assays as previously performed for other mutations in other laboratories.
In addition, we tested for CYP17A1 promoter activation and an effect on steroid enzyme activ-
ity as well as for variable expression of WT and mutant MAMLD1 proteins. Overall, all these
studies were not giving conclusive results to explain the role of MAMLD1 gene variants for
abnormal sex development. Similar confounding results for functional studies are found in the
published literature [Table 3 and [5, 11, 14]]. Although studies in mice revealed a role of
MAMLD1 for Cyp17 gene expression and activity [13], our WTMAMLD1 was only able to
modulate the human CYP17A1 promoter activity, but had no effect on steroid conversion and
thus enzyme activity. Human MAMLD1 does not bind to theHes3 promoter or to the human
HES3 upstream region directly [14]. Therefore, it has been proposed that MAMLD1 may act
through other partners such as the Hes3-DNA-binding transcription factor [14], but to date
such partners remain obscure. Our in silico search for possible interacting partners of human
MAMLD1 was negative when using tools to search for functional partners (string-db.org) or
for physical or genetic interactions (http://thebiogrid.org).
To date, twenty-sevenMAMLD1 sequence variations are described, including the 7 novel
variants described in this study (Tables 1 and 3). They are all located between exon 4 and
intron 6 (Fig 1B) and show the following genotype-phenotype characteristics. Most mutations
are only found in DSD patients which present with a broad range of mild to severe phenotype
[c325delG (6), S143X [6], E182fsX121 [4], E197X, [3], T202M (present study), L210X and
D211N (present study), Q270X, [3], H347Q [6] (present study), P384L [6], Q501Q502 (present
study), A503E (present study), Q580R [3], Q602K [7], K682fsX1070 [9], 614ins3Q [4], P677L
[10], L724V (present study), R726X, [3], S730S (present study), D759D [7]]. Others are carried
by patients and controls [P359S [3, 5, 7] (present study), V505A [4, 7] (present study),
604ins3Q [7], N662S [3, 5–7] (present study)]. MAMLD1 R371X is only described in a control
[31]. Finally, in two independent families MAMLD1 mutations [P359S and Q580R [3]] were
not found in all 46,XY DSD family members. Thus, genotype-phenotype correlation of
MAMLD1 sequence variations and 46,XY DSD is poor.
MAMLD1 gene variations are also reported in other species, both male and female, and
with and without abnormalities in sex development [15–17]. Yet none of them has been clearly
related to the DSD phenotype. In dogs, both DSD and controls were carriers [15], in cats only
an intronic change has been described [16], and in a male horse with hypospadias a benign
mutation was detected, conserved in allMAMLD1 sequences available at that time [17].
MAMLD1 seems involved in sexual development during fetal life. It is expressed in human
fetal testes and ovaries [3, 32], and in mice testes [3, 13].Mamld1 is present in mice testes at
least from E11.5 which overlaps with the start of androgen biosynthesis (13 dpc) and with the
formation of the male external genitalia (16.5 dpc) [13].Mamld1 is expressed at low levels in
postnatal mice testes until 1 week of age [3, 33]. In human fetal testes, MAMLD1 is expressed
at high levels in the second trimester of gestation [3, 32]. In addition, our study shows that it is
also expressed in human adult testes and adrenals, but not in fetal adrenal tissue. These results
suggest that MAMLD1 may not only have a role during fetal development but also in adult life.
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In mice, Mamld1 regulates the expression of steroidogenic enzymes Cyp17a1, Cyp11a1,
Star,Hsd3b1, Hsd17b3, and of genes involved in testes descent (Amh and Insl3) [13, 20]. It
seems involved in testosterone production by regulating Cyp17a1 activity and expression [20].
However,Mamld1-KO mice develop normal external genitalia and have normal reproduction,
which both depend on testosterone production and Cyp17 activity [13]. Overall, these results
challenge the role of MAMLD1 in sex development.
In conclusion, the importance of MAMLD1 in the sexual development becomes less and
less clear. Its exact role remains unknown. Studies of MAMLD1 variations in humans suggest
that there is a genetic correlation between MAMLD1 sequence variations and DSD. However,
the wide range in phenotype and poor genotype-phenotype correlation indicate that
MAMLD1 gene variations may not suffice to explain the DSD pathology. Therefore, in DSD
patients harboring MAMLD1 sequence variations further genetic studies should be performed
searching for additional genetic hits explaining the immense variability. This may be done by
specific DSD chips containing a larger array of known genes involved in DSD, which are cur-
rently being used in several DSD research projects and should become available soon. Alterna-
tively, an untargeted approach like exome sequencing might be employed that also allows to
find novel genes so far unrevealed in DSD [34]. In addition, to find copy number variations
array-based comparative genomic hybridization (aCGH) or multiplex ligation-dependent
probe amplification (MLPA) may be used [35]. Although so far no multiple hits in DSD genes
were described involving MAMLD1, it would not be surprising to find them in the near future
with the above mentioned next generation methods.
Supporting Information
S1 Fig. MAMLD1 alignment in mammalian species.Human MAMLD1 (isoform 2, 774
amino acids) was aligned with homologous sequences from 40 mammalian species (length
range from 720–820 amino acids). L210 and L724 (1 change each) are conserved along mam-
malian evolution, followed by S730 (deleted amino acid in 2 species). T202, D211, P359,
Q501Q502, A503, V505 and N662 are not conserved, all ranging from 1 to 6 changes. Human
changes in positions 202, 347, 505 and 662 present WT in other mammals. The alignments
were performed with the CLC Sequence Viewer software (2014 CLC bio, QIAGEN) and show
the species common name and the NCBI database (www.ncbi.nlm.nih.gov) accession name/s
in brackets. Human: Homo sapiens; chimpanzee: Pan troglodytes; pygmy chimpanzee: Pan
paniscus; western lowland gorilla: Gorilla gorilla gorilla; crab-eating macaque:Macaca fascicu-
laris; pig-tailed macaque:Macaca nemestrina; sooty mangabey: Cercocebus atys; green monkey:
Chlorocebus sabaeus; white-tufted-ear marmoset: Callithrix jacchus; small-eared galago: Otole-
mur garnettii; Sunda flying lemur: Galeopterus variegatus; Chinese tree shrew: Tupaia chinen-
sis; Cape golden mole: Chrysochloris asiatica; thirteen-lined ground squirrel: Ictidomys
tridecemlineatus; rabbit: Oryctolagus cuniculus; American pika: Ochotona princeps; house
mouse:Mus musculus; prairie deer mouse: Peromyscus maniculatus bairdii; Chinese hamster:
Cricetulus griseus; prairie vole:Microtus ochrogaster; Damara mole-rat: Fukomis damarensis;
Iesser Egyptian jerboa: Jaculus jaculus; big brown bat: Eptesicus fuscus; horse: Equus caballus;
Bactrian camel: Camelus bactrianus; dog: Canis lupus familiaris; alpaca: Vicugna pacos; pig: Sus
scrofa; southern white rhinoceros: Ceratotherium simum simum; Pacific walrus: Odobenus ros-
marus divergens; bottlenosed dolphin: Tursiops truncatus; Yangtze River dolphin: Lipotes vexil-
lifer; Florida manatee: Trichechus manatus latirostris; killer whale: Orcinus orca; sperm whale:
Physeter catodon; sheep: Ovis aries; goat: Capra hircus; chiru: Pantholops hodgsonii; cattle: Bos
taurus; water buffalo: Bubalus bubalis; nine-banded armadillo: Dasypus novemcinctus.
(PDF)
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S2 Fig. Effect of WT and mutant MAMLD1 on CYP17A1 enzyme activity in HEK293 and
MA-10 cells. Cells were transiently transfected with MAMLD1WT and mutant expression
vectors. HEK293 cells were also co-transfected with the CYP17A1 expression vector as they do
not express it endogenously. The effect of WT and mutant MAMLD1 on CYP17A1 enzyme
activity was assessed by measuring the conversion of progesterone (P) to 17-hydroxyprogester-
one (17OHP) in non-steroidogenic HEK293 cells, and conversion of P to 17OHP and then to
androstenedione (Δ4A) in steroidogenic mouse Leydig MA-10 cells. Steroid production was
labeled with [14C]progesterone for 60 min. Steroids were extracted and resolved by thin-layer
chromatography, then quantified as % conversion. A representative steroid profile obtained
from HEK293 (A) and MA-10 (B) cells is shown (n = 2). Similar to experiments performed in
NCI-H295R cells (Fig 3B), no effect of MAMLD1 on CYP17-hydroxylase activity was detected.
Ve: empty vector; WT: wild type; : co-transfected with empty vector; NT: non-transfected.
(TIF)
S3 Fig. Protein expression of MAMLD1. Picture of the original uncropped and unadjusted
Western blots for myc-MAMLD1 (A) and actin (B) corresponding to Fig 4. Ve: empty vector;
WT: wild type; NT: non-transfected.
(TIF)
S1 File. Relevant experimental data. Data corresponding to the transactivation studies are
provided, which include: raw data from the luciferase assays, values behind statistics and origi-
nal graphs.
(XLSX)
S1 Table. Primers used in this study.
(DOCX)
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